Tauklarify (florquinitau F 18) is a brain PET tracer that highlights tau tangles, twisted tau deposits checked during an Alzheimer's evaluation, while Alzheimer's blood tests help assess amyloid pathology from a blood draw. For primary care patients in 2026, blood testing is often the first diagnostic aid and tau PET is a focused follow-up when tau information would shape care. The U.S.
FDA lists Tauklarify as approved on Aug. 13, 2026, for brain PET in cognitively impaired adults evaluated for Alzheimer's to identify tau tangle pathology, as described in the FDA 2026 novel drug approvals page. Blood options cleared for symptomatic adults include amyloid-related plasma measures such as pTau217 and amyloid ratios. The practical choice is not which test is better in general, but which question each test answers for you.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does each test show?
- Who are these tests for?
- How accurate are blood tests, and when is PET or spinal fluid still needed?
- What questions should you bring to primary care?
What does each test show?
Tauklarify PET shows the location and extent of tau tangle pathology in the brain at scan time. A radiologist reads the image as positive or negative for the Alzheimer's-related tau pattern. It does not measure memory, diagnose dementia by itself, or replace a clinical exam. Blood tests estimate the likelihood of Alzheimer's-related amyloid pathology from plasma markers.
Examples include a pTau217-to-amyloid ratio, a single pTau217 measure, or a combined amyloid-plus-pTau217 score. They are laboratory aids that a clinician interprets with symptoms, history, cognitive testing, and other findings. The two approaches can disagree because they track different proteins and disease stages. Tau PET adds spatial detail about tangles, while blood gives a probability about amyloid pathology without brain images. Ask your clinician which protein question matters most for your symptoms and treatment options.
Who are these tests for?
Tauklarify is for adults with cognitive impairment who are already being evaluated for Alzheimer's disease. It is not indicated for tau diseases other than Alzheimer's, according to labeling summarized by Pharmacy Times in the Pharmacy Times approval summary. A primary care clinician usually refers eligible patients to a PET center rather than ordering the scan directly. Blood tests cleared in 2025 and 2026 are also for people with signs or symptoms, not for routine screening without symptoms.
The FDA-cleared uses name adults 55 and older with signs, symptoms, or cognitive complaints, while one mass-spectrometry option is cleared for symptomatic adults 40 and older. Age cutoff, symptom status, pregnancy, recent illness, kidney disease, and medicines can affect eligibility and interpretation, so bring a complete list. A normal exam with only worry about future risk does not fit either pathway. In that case, ask about brain-health follow-up, repeat cognitive checks, hearing and vision care, sleep, mood, vascular risks, and when re-evaluation makes sense. That plan protects time and money when testing would not change care.
How accurate are blood tests, and when is PET or spinal fluid still needed?
The Alzheimer's Association guideline released July 29, 2025, sets a clear bar: blood tests with at least 90% sensitivity and 90% specificity can substitute for amyloid PET or spinal-fluid testing, while tests meeting at least 90% sensitivity and 75% specificity are triage tools that need PET or spinal-fluid confirmation when positive, as stated in the Association guideline announcement. A prospective JAMA 2024 study by Palmqvist and colleagues found one combined blood score reached about 90% accuracy against PET or spinal fluid. Your clinician can check which accuracy tier your offered test meets. An intermediate or likely-positive blood result deserves special care. NeurologyLive reports that the intermediate likely-positive result occurred in 17.3% of patients and carried only 77.3% positive predictive value, so many patients in that group need confirmation, as explained in the NeurologyLive test-clearance report.
Ask whether your result is negative, positive, or intermediate, and what cutoff your laboratory used. Also ask how a positive triage result would be confirmed before treatment, referral, or planning decisions. PET has limits too. A negative tau scan does not exclude tau pathology, and a positive scan does not by itself confirm Alzheimer's disease at tissue examination. Scan availability, radiation exposure, contrast or tracer allergies, claustrophobia, cost, prior authorization, and travel distance also matter. Get the confirmation plan in writing before blood is drawn.
What questions should you bring to primary care?
Bring a short symptom timeline, daily-life examples, medicines, and a family member who sees you often. Ask what diagnosis is being considered and how each result would change referral, treatment, safety planning, or support services. Clear questions shorten the visit and reduce repeat testing.
End by asking for next steps for each possible result. Request a written plan for negative, positive, and intermediate outcomes, including driving, work, medications, advance planning, and follow-up timing. Bring that plan to any specialist visit so PET and blood results stay linked to care.
- Would a blood test help now, which exact test do you use, and what accuracy tier does it meet?
- Am I in the cleared group by age and symptoms, and what could distort my result?
- If blood is positive or intermediate, will you order amyloid PET, spinal-fluid testing, or tau PET, and where?
- If tau PET is suggested, what added decision depends on tau rather than amyloid?
- What are out-of-pocket cost, prior authorization, wait time, and how will results reach me?
You Might Also Like
- Young-Onset Dementia Cost Gaps Identified by NIA in 2026: Questions Working Dementia Caregivers Can Ask Local Care Programs
- Day-One Subcutaneous Leqembi for Early Alzheimer’s in 2026: How Family Caregivers Can Compare Treatment Routes
- AAIC 2026 Primary Care Alzheimer’s Blood Test Findings: What Is Established and What Remains Uncertain for Younger-Onset Alzheimer’s Families
